MacroGenics (MGNX) Competitors $1.56 -0.23 (-12.85%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. TYRA, UPB, CGEM, OPT, AKBA, PGEN, ANAB, MAZE, TRVI, and SAGEShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Tyra Biosciences (TYRA), Upstream Bio (UPB), Cullinan Therapeutics (CGEM), Opthea (OPT), Akebia Therapeutics (AKBA), Precigen (PGEN), AnaptysBio (ANAB), Maze Therapeutics (MAZE), Trevi Therapeutics (TRVI), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Tyra Biosciences Upstream Bio Cullinan Therapeutics Opthea Akebia Therapeutics Precigen AnaptysBio Maze Therapeutics Trevi Therapeutics Sage Therapeutics Tyra Biosciences (NASDAQ:TYRA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Is TYRA or MGNX more profitable? Tyra Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Tyra Biosciences' return on equity of -24.56% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets Tyra BiosciencesN/A -24.56% -23.31% MacroGenics -69.07%-89.42%-38.57% Do insiders & institutionals have more ownership in TYRA or MGNX? 84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by insiders. Comparatively, 11.3% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend TYRA or MGNX? Tyra Biosciences currently has a consensus target price of $30.50, indicating a potential upside of 197.85%. MacroGenics has a consensus target price of $7.38, indicating a potential upside of 372.76%. Given MacroGenics' higher probable upside, analysts plainly believe MacroGenics is more favorable than Tyra Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Does the media prefer TYRA or MGNX? In the previous week, MacroGenics had 14 more articles in the media than Tyra Biosciences. MarketBeat recorded 17 mentions for MacroGenics and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.67 beat MacroGenics' score of -0.14 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MacroGenics 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community favor TYRA or MGNX? MacroGenics received 392 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 75.56% of users gave Tyra Biosciences an outperform vote while only 62.10% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformTyra BiosciencesOutperform Votes3475.56% Underperform Votes1124.44% MacroGenicsOutperform Votes42662.10% Underperform Votes26037.90% Which has preferable earnings & valuation, TYRA or MGNX? MacroGenics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTyra BiosciencesN/AN/A-$69.13M-$1.61-6.36MacroGenics$148.34M0.66-$9.06M-$1.08-1.44 Which has more risk and volatility, TYRA or MGNX? Tyra Biosciences has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. SummaryMacroGenics beats Tyra Biosciences on 10 of the 18 factors compared between the two stocks. Remove Ads Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.91M$6.96B$5.65B$8.15BDividend YieldN/A2.73%4.55%4.02%P/E Ratio-0.997.2024.5319.08Price / Sales0.66227.46385.0894.26Price / CashN/A65.6738.1634.64Price / Book0.636.486.954.36Net Income-$9.06M$142.85M$3.20B$247.14M7 Day Performance-28.44%-3.40%-2.35%-0.99%1 Month Performance-37.35%-5.32%2.26%-5.42%1 Year Performance-89.03%-7.11%12.92%3.44% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics3.9276 of 5 stars$1.56-12.8%$7.38+372.8%-87.6%$97.91M$148.34M-0.99430Earnings ReportAnalyst ForecastTYRATyra Biosciences1.8408 of 5 stars$10.74-6.6%$30.50+184.0%-37.4%$543.48MN/A-6.6720Upcoming EarningsPositive NewsUPBUpstream BioN/A$9.87+2.7%$56.50+472.4%N/A$529.44M$2.37M0.0038Positive NewsCGEMCullinan Therapeutics2.4551 of 5 stars$9.03+2.7%$32.86+263.9%-51.0%$528.37MN/A-3.1830OPTOpthea0.6611 of 5 stars$3.41+7.1%$12.00+252.4%-11.0%$524.07M$87,666.000.008Analyst DowngradeNews CoverageGap UpAKBAAkebia Therapeutics3.8612 of 5 stars$2.40+6.2%$6.75+181.3%-11.8%$523.63M$169.88M-10.43430PGENPrecigen3.5451 of 5 stars$1.78-1.1%$7.00+293.3%+21.7%$521.31M$3.96M-3.24190Earnings ReportAnalyst RevisionGap UpANABAnaptysBio3.4797 of 5 stars$16.51-1.3%$35.11+112.7%-12.6%$506.31M$91.28M-2.72100Buyback AnnouncementNews CoverageHigh Trading VolumeMAZEMaze TherapeuticsN/A$11.49+4.5%$25.67+123.4%N/A$503.00M$167.50M0.00121TRVITrevi Therapeutics3.6265 of 5 stars$6.54-3.1%$15.94+143.7%+97.3%$502.70MN/A-14.8620High Trading VolumeSAGESage Therapeutics3.2297 of 5 stars$8.02+3.9%$8.81+9.9%-54.4%$493.08M$41.24M-1.22690 Remove Ads Related Companies and Tools Related Companies Tyra Biosciences Alternatives Upstream Bio Alternatives Cullinan Therapeutics Alternatives Opthea Alternatives Akebia Therapeutics Alternatives Precigen Alternatives AnaptysBio Alternatives Maze Therapeutics Alternatives Trevi Therapeutics Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGNX Stock Free MGNX Stock Alerts